Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Towards an AIDS vaccine: unusual antibody that targets HIV described by scientists at TSRI

27.06.2003


A group of scientists from The Scripps Research Institute (TSRI) and several other institutions has solved the structure of an antibody that effectively neutralizes human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS).



The antibody binds to sugars on the surface of HIV and effectively neutralizes the virus because of its unique structure, which is described in the latest issue of the journal Science.

"What we found was an unusual configuration of the antibody in which its two Fab domains -- the antigen recognition units -- are ’interdigitating’ with each other," says TSRI Professor Ian Wilson, D.Phil., one of two TSRI professors who led the research. "Nothing like this has ever been seen before."


This new structure is an important step toward the goal of designing an effective vaccine against HIV, and it gives the researchers a new way to design antibodies in general.

"It may enable us to make antibodies that recognize whole new sets of molecules," says TSRI Professor Dennis Burton, Ph.D., the other TSRI professor who led the research.

The Problem of HIV and Antibodies

HIV causes AIDS by binding to, entering and ultimately, killing T helper cells, immune cells that are necessary to fight off infections by common bacteria and other pathogens. As HIV depletes the body of T helper cells, common pathogens can become potentially lethal.

The latest statistics are grim. The World Health Organization estimates that around 40 million people are living with HIV worldwide. During 2001 alone, more than four million men, women, and children succumbed to the disease, and by the end of that year, the disease had made orphans of 14 million children. In the United States, 40,000 people are infected with HIV each year.

One of the most compelling medical challenges today is to develop a vaccine that will provide complete prophylactic protection to someone who is later exposed to this virus. An important part of such a vaccine will be a component that elicits or induces effective neutralizing antibodies against HIV in the blood of the vaccinated person.

Also called immunoglobins, antibodies are the basis for many existing vaccines, including those against measles, polio, hepatitis B, and hepatitis A. HIV antibodies are produced by the body’s B cells after HIV enters the bloodstream. During such an immune response, the antibodies circulate through the blood. Good antibodies bind to and "neutralize" the virus, making it unable to invade cells. Because neutralizing antibodies attack the virus before it enters cells, they could conceivably be used to prevent HIV infection if they were present prior to virus exposure. A vaccine would seek to elicit these neutralizing antibodies.

This is easier said than done. The body makes lots of antibodies against HIV, but they are almost always unable to neutralize the virus. Much of the viral surface is coated with carbohydrates (sugars), which are hard for the immune system to attack because these sugars are made by human cells and attached by human proteins. In other words, they are "self" and should not be recognized by antibodies.

However, in rare instances some people have produced antibodies that broadly neutralize HIV. One such antibody, called 2G12, was isolated from an HIV-positive individual about a decade ago by Hermann Katinger, a doctor at the Institute for Applied Microbiology of the University of Agriculture in Vienna, Austria and one of the authors on the paper. This antibody is not like ordinary antibodies.

"The Fab [antigen recognition] arms are interlocked," says Burton. "That is a unique arrangement, and it is good for recognizing a cluster of shapes like sugars on a virus."

The 2G12 antibody forms an unusual "dimer" interface where two antibodies create an unusual multivalent binding interface with multiple binding sites that recognizes an unusual arrangement of 2-3 "oligomannose" sugars on the surface of protein spikes called gp120 that decorate the coat of HIV. This allows the antibody to properly target HIV virions as foreign pathogens. The sugars are human but their arrangement is foreign-and it is this arrangement that the antibodies recognize.

These results are a step in the direction of designing an effective AIDS vaccine because it reveals what these neutralizing antibodies should look like. The next step is to use the structure of the antibody as a template to design an "antigen" that would stimulate the human immune system to make 2G12 or similar broadly neutralizing antibodies against HIV.

The results are also important because the structure of the antibody is something that has never been seen before. "Can we now," asks Wilson, "use this [knowledge] to engineer antibodies with higher affinity against other antigens or clusters of antigens?"



The TSRI study combined experts from several institutions besides TSRI, including Pauline M. Rudd, Ph.D., and Raymond A. Dwek, D.Phil., D.Sc., FRS, from the Glycobiology Institute at Oxford University in the United Kingdom. Also involved in the study were researchers in the Department of Biological Science and Structural Biology at Florida State University in Tallahassee.

The research article, "Antibody Domain Exchange is an Immunological Solution to Carbohydrate Cluster Recognition" is authored by Daniel A. Calarese, Christopher N. Scanlan, Michael B. Zwick, Songpon Deechongkit, Yusuke Mimura, Renate Kunert, Ping Zhu, Mark R.Wormald, Robyn L. Stanfield, Kenneth H. Roux, Jeffery W. Kelly, Pauline M. Rudd, Raymond A. Dwek, Hermann Katinger, Dennis R. Burton, and Ian A. Wilson and appears in the June 27, 2003 issue of the journal Science.

The research was supported by The Skaggs Institute for Research, which funds The Skaggs Institute for Chemical Biology at TSRI. TSRI is one of the world’s largest, private, non-profit biomedical research organizations and is internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases and synthetic vaccine development. It is dedicated to the creation of basic knowledge in the biosciences for medical application and the betterment of human health, to the pursuit of fundamental scientific advances through interdisciplinary programs and collaborations, and to the education and training of researchers from around the world preparing to meet the scientific challenges of the future.

Grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of General Medical Sciences (NIGMS) also supported this research. NIGMS is part of the National Institutes of Health (NIH), U.S. Department of Health and Human Services and supports basic biomedical research that lays the foundation for advances in disease diagnosis, treatment, and prevention. NIGMS also trains tomorrow’s scientists and makes special efforts to increase the number of minority researchers. A component of the NIH, NIAID conducts and supports research that strives to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten hundreds of millions of people worldwide. NIAID’s mission is driven by a strong commitment to basic research and the understanding that the fields of immunology, microbiology, and infectious disease are related and complementary.

The research is further supported by the International AIDS Vaccine Initiative (IAVI). Burton and Wilson are part of the multi-million-dollar Neutralizing Antibody Consortium launched last year by IAVI, a global nonprofit organization working to speed scientific progress toward developing safe and effective vaccines to prevent HIV/AIDS that will be accessible worldwide. IAVI’s work focuses on four areas: mobilizing support through advocacy and education, accelerating scientific progress, encouraging industrial participation in AIDS vaccine development, and assuring global access. Burton is the director of the Neutralizing Antibody Consortium.

Jason Bardi | EurekAlert!
Further information:
http://www.scripps.edu/

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>